Loading stock data…
$10.28+0.10 (+0.98%)
Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. in the Healthcare sector is trading at $10.28 with a market capitalization of $373M. Wall Street consensus targets $17.67 (6 analysts), implying a +71.9% move over the next 12 months. The stock is currently 22% below its 52-week high of $13.25, remaining 13.7% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $17.87M↑ | $15.11M↑ | $13.78M↑ | $12.46M↑ | $9.65M |
| Gross Profit | $17.15M↑ | $14.54M↑ | $12.01M↑ | $11.80M↑ | $8.69M |
| Operating Income | $1.74M↑ | -$119,000↑ | -$2.58M↓ | -$201,000↑ | -$2.73M |
| Net Income | $1.97M↑ | $201,000↑ | -$4.79M↓ | -$638,000↑ | -$3.15M |
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pedia...